Padcev

News

FDA starts speedy review of Imfinzi in bladder cancer

AstraZeneca is closing on FDA approval of a new bladder cancer indication for Imfinzi that could help to fend off encroachment from MSD's Keytruda.

News

Pfizer targets $2.5bn more in cost savings

Pfizer's second-quarter results update is headlined by news of an additional $2.5 billion in cost-cutting initiatives.

News

Astellas' Padcev and Gilead's Trodelvy grab key EU approvals

New approvals in the EU for Astellas' Padcev and Gilead's Trodelvy break new ground in the treatment of bladder and triple-negative breast cancer.

News

AZ cues up broader use of Imfinzi in bladder cancer

The results of the VOLGA trial have buoyed AstraZeneca's ambitious growth targets for PD-L1 inhibitor Imfinzi in bladder cancer.

News

Padcev/Keytruda scores again in early bladder cancer

Pfizer and Astellas now have two studies supporting the use of Padcev with MSD's Keytruda as perioperative therapy for muscle-invasive bladder cancer.

News

EMA starts review of 'transformative' bladder cancer therapy

The EMA has started a review of a regimen based on Pfizer/Astellas' Padcev and MSD's Keytruda that is described as a game-changer for bladder cancer.

FDA starts speedy review of Imfinzi in bladder cancer

Pfizer targets $2.5bn more in cost savings

Astellas' Padcev and Gilead's Trodelvy grab key EU approvals

AZ cues up broader use of Imfinzi in bladder cancer

Padcev/Keytruda scores again in early bladder cancer

EMA starts review of 'transformative' bladder cancer therapy

Iambic prices its IPO, seeking to raise up to $160m

Discover a new era of healthcare panel engagement: Grounded ...

Padcev

Editor's Picks